BlackRock Institutional Trust’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

BlackRock Institutional Trust’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.46M	Buy	433,052 +17,420	+4%	+$159K	﹤0.01%	2773
2016 Q3	$4.2M	Sell	415,632 -7,565	-2%	-$82.6K	﹤0.01%	2766
2016 Q2	$4.75M	Buy	423,197 +17,248	+4%	+$220K	﹤0.01%	2709
2016 Q1	$5.54M	Sell	405,949 -56,796	-12%	-$817K	﹤0.01%	2600
2015 Q4	$8.78M	Buy	462,745 +45,414	+11%	+$987K	﹤0.01%	2411
2015 Q3	$7.83M	Buy	417,331 +204,622	+96%	+$3.48M	﹤0.01%	2448
2015 Q2	$3.17M	Buy	212,709 +99,903	+89%	+$1.52M	﹤0.01%	2939
2015 Q1	$1.71M	Buy	112,806 +49,619	+79%	+$692K	﹤0.01%	3181
2014 Q4	$842K	Buy	63,187 +2,941	+5%	+$38K	﹤0.01%	3392
2014 Q3	$760K	Sell	60,246 -15,672	-21%	-$152K	﹤0.01%	3403
2014 Q2	$767K	Sell	75,918 -44,328	-37%	-$428K	﹤0.01%	3496
2014 Q1	$1.62M	Buy	+120,246	New	+$1.7M	﹤0.01%	3253

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock Institutional Trust's CNCE Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Concert Pharmaceuticals, Inc. (CNCE) stake by 4.2% in Q4 2016, buying an estimated $159K and bringing the position to 433,052 shares worth $4.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2773.

BlackRock Institutional Trust first reported a position in CNCE in Q1 2014 and has held it in 12 quarters since. The position peaked at $8.78M in Q4 2015. 89 funds tracked by Wall St. Rank hold CNCE as of Q4 2016.

BlackRock Institutional Trust held 433,052 shares of Concert Pharmaceuticals, Inc. worth $4.46M as of Q4 2016.
BlackRock Institutional Trust bought 17,420 Concert Pharmaceuticals, Inc. shares in Q4 2016, an estimated $159K.
Concert Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2773 holding.
BlackRock Institutional Trust first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Institutional Trust's Concert Pharmaceuticals, Inc. position peaked at $8.78M in Q4 2015.
89 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.